上海医药(601607.SH)：多西环素胶囊获得美国FDA批准文号

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory, received a notification from the U.S. Food and Drug Administration (FDA) regarding doxycycline capsules [1] Group 1 - The notification from the FDA pertains to the approval status of doxycycline capsules produced by the Changzhou Pharmaceutical Factory [1] - The company is expected to provide further details on the implications of this FDA notification in future communications [1]